So if it is "significant" information that "might have a material effect on the share price" Dr Perin can telegraph it (since April) and him and SI (and who knows who else) can be aware of it for months, and a bunch of AHA strangers (and who knows who else) will have been aware of it for over a month, and maybe the NEJM (and who knows who else), but it still meets price sensitive listing rules?
Seems to be stretching the realms of credibility a bit to me and could attract the attention of the ambulance chasers, but then again, what would a simpleton like me know.
Anyway, the Ecoool Guru seems convinced and is talking it up big time, so it must be true, even thinks "big pharma...all be listening in to EP’s talk":
LINK"Meanwhile the American Heart Association’s scientific sessions have given Emerson Perin a “late breaking” talking session on 14 November. That is usually reserved for important papers which have just come out - most other presenters at the world’s foremost heart association will be presenting papers which were lodged months ago.This is a strong indication that EP’s long awaited article in the NEJM is imminent - maybe timed to come out around the time of the conference.The AHA conference usually has 15,000 heart specialists attending - so this is a very big deal for Meso, though I had previously flagged it was possible given EP’s comments back in April.
Do you really think the AHA would include EP’s work as a late breaker if it wasn’t significant. Will it be bad news or good? He has already told us on his video talks that he has had spectacular results and he thinks it will change how we treat heart disease and he’s the director of the Texas Heart Institute - one of the biggest in the world. He’s a big hitter with great results presenting to the biggest group of big hitters in the world! My money’s on a real scramble by potential big pharma partners in the heart indication once EP has done his presentation - they are already talking to Meso as the Prof has previously told us, but they’ll all be listening in to EP’s talk and we should have the NEJM article and the FDA giving us a pathway to approval meeting around the same time."
*Tread carefully mums and dads and newbies when making your buying/selling/holding decisions and beware the super spruikers hyperbole.
(20min delay)